<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568607</url>
  </required_header>
  <id_info>
    <org_study_id>DICE-NK/T</org_study_id>
    <nct_id>NCT00568607</nct_id>
  </id_info>
  <brief_title>Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma</brief_title>
  <official_title>Phase II Study of a Combination Chemotherapy of DICE in the Patients With NK/T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and tolerability of the combination
      chemotherapy of DICE in the patients with NK/T cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with NK/T cell lymphoma usually have a bad prognosis. These patients cannot be
      treated successfully with the conventional chemotherapy of CHOP.The investigators did this
      trial to evaluate the efficacy and tolerability of the combination chemotherapy of DICE in
      the patients with NK/T cell lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>every two cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TTP and OS</measure>
    <time_frame>every two cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>IFO, VP-16, DDP, DXM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFO, VP-16, DDP, DXM</intervention_name>
    <description>DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.</description>
    <arm_group_label>IFO, VP-16, DDP, DXM</arm_group_label>
    <other_name>DICE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range 18-75 years old

          -  Histological confirmed NK/T cell lymphoma

          -  ECOG performance status less than 2

          -  Life expectancy of more than 3 months

          -  None of major drugs in the trial (IFO,VP16,DDP) has been previously used

          -  Normal laboratory values: hemoglobin &gt; 80 g/dl, neutrophil &gt; 2×109/L, platelet &gt;
             100×109/L, serum creatine &lt; 1.5×upper limitation of normal (ULN), serum bilirubin &lt;
             1.5×ULN, ALT and AST &lt; 2.5×ULN

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Serious uncontrolled diseases and intercurrent infection

          -  The evidence of CNS metastasis

          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Guo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ye Guo, MD</last_name>
    <phone>862164175590</phone>
    <phone_ext>3252</phone_ext>
    <email>pattrick_guo@msn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biyun Wang, MD</last_name>
      <phone>8613701748410</phone>
      <email>wangbiyun@msn.com</email>
    </contact>
    <investigator>
      <last_name>Biyun Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>September 7, 2010</last_update_submitted>
  <last_update_submitted_qc>September 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Base for Drug Clinical Trials, Fudan University Cancer Hospital</name_title>
    <organization>Fudan University Cancer Hospital</organization>
  </responsible_party>
  <keyword>NK/T cell lymphoma</keyword>
  <keyword>Response Rate</keyword>
  <keyword>TTP</keyword>
  <keyword>OS</keyword>
  <keyword>Toxicities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

